Thursday, April 30, 2026
Scientific trial suggests semaglutide could assist sufferers with alcohol use dysfunction and weight problems.
A group of Nationwide Institutes of Well being (NIH) scientists and worldwide colleagues have reported the primary proof from a randomized managed medical trial indicating {that a} GLP-1 receptor agonist can cut back the times wherein sufferers with weight problems and alcohol use dysfunction have interaction in heavy consuming. Led by researchers at Copenhagen College Hospital, the brand new examine provides to a rising physique of proof suggesting that GLP-1s might be helpful in treating alcohol use dysfunction.
“Only a few medicines are presently accredited for alcohol use dysfunction, and these are vastly underutilized. A brand new choice that’s extra accessible and more practical might be a gamechanger for closing the therapy hole,” stated Director of NIH’s Nationwide Institute on Alcohol Abuse and Alcoholism (NIAAA) George Koob, Ph.D., a examine co-author.
Analysis has more and more instructed that GLP-1s accredited for weight reduction could profit these with substance use issues. Whereas one latest medical trial discovered {that a} GLP-1 had no impact on the heavy consuming of examine individuals as an entire group, a subset who had weight problems responded strongly.
The authors of the brand new examine particularly enrolled 108 treatment-seeking sufferers with alcohol use dysfunction and comorbid weight problems. Along with normal cognitive behavioral remedy, individuals acquired both a placebo or a dose of semaglutide on a weekly foundation for 26 weeks. All through the trial, the researchers collected self-reported consuming information in addition to measurements of a number of quantitative biomarkers.
They discovered that individuals receiving semaglutide skilled a 41.1% discount in heavy consuming days, a 13.7% better discount than that of the placebo group. Measurements of blood-alcohol biomarkers supported the self-reported-data-based findings. As anticipated, the researchers noticed that decreases in body weight, blood strain, and different medical measures had been extra pronounced within the GLP-1 group. The authors took word of some antagonistic results, together with gastrointestinal signs, although they had been transient and gentle.
The researchers additionally discovered that semaglutide might probably result in constructive outcomes extra usually than different medicines for alcohol use dysfunction, as its quantity wanted to deal with (NNT) — a metric of medical efficacy — on this examine was 4.3, whereas the NNT of accredited medicines is 7 or increased.
“We’re starting to see a few of that potential for GLP-1s to deal with drug habit flip into actuality. Questions stay however that is nonetheless very encouraging,” stated Director of NIH’s Nationwide Institute on Drug Abuse (NIDA) and examine co-author Nora Volkow, M.D.
Subsequent, the authors want to look at the consequences of GLP-1s over an extended length and in a bigger inhabitants to verify their findings right here.
The scientific group was led by first writer Mette Kruse Klausen, M.D., and corresponding writer Anders Fink-Jensen, D.M.Sc., at Copenhagen College Hospital.
Concerning the Nationwide Institutes of Well being (NIH): NIH, the nation’s medical analysis company, consists of 27 Institutes and Facilities and is a element of the U.S. Division of Well being and Human Companies. NIH is the first federal company conducting and supporting fundamental, medical, and translational medical analysis, and is investigating the causes, therapies, and cures for each frequent and uncommon ailments. For extra details about NIH and its applications, go to www.nih.gov.
NIH…Turning Discovery Into Well being®
Reference
Mette Kruse Klausen et al. As soon as-weekly semaglutide versus placebo in sufferers with alcohol use dysfunction and comorbid weight problems: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026. DOI: 10.1016/S0140-6736(26)00305-3
